News | October 15, 2021
Expect normal quarter in Q2FY22: Emkay
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Since its inception, the company has either acquired or taken a majority stake in five companies
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
In collaboration with RAND Europe, the Vitality calculator predicts an individual's healthspan and future health risks
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The injection is used to reverse the effects of the muscle relaxants given to patients during surgery
The company will use the capital for building its team, product development, marketing, and setting up in-school clinics to deliver connected health to one million families
FUJIFILM will distribute iSWAB bio sampling technologies in Japan
According to industry sales data, the 10mg strength of Afinitor generated annual sales of US $ 392 million during the twelve months ending July 2021
Subscribe To Our Newsletter & Stay Updated
